Sarcomatrix Opens New Funding Round to Advance Muscular Dystrophy Treatment
Las Vegas, Wednesday, 15 July 2026.
Sarcomatrix Therapeutics has launched a Seed+ funding round on KoreInside, aiming to transition its promising oral muscular dystrophy treatment into human clinical trials by 2027.
Strategic Capital for Clinical Milestones
On July 15, 2026, Reno, Nevada-based biotechnology firm Sarcomatrix Therapeutics Corp. announced the opening of its Seed+ funding round. The company, which is privately held and does not have a ticker symbol, is advancing its therapeutic pipeline with this capital infusion. The Seed+ round opened on July 14, 2026, and was officially announced on July 15, 2026. Sarcomatrix Therapeutics Corp. is focused on clinical milestones scheduled for 2027, including an IND filing in early 2027 and first-in-human trials later that year. The company’s development efforts build on progress demonstrated at the BIO event in June 2026.